2023 WMIF | The Disruptors: The Biologic Revolution in Cancer Continues

The Disruptors: The Biologic Revolution in Cancer Continues
A new generation of oncology drugs is emerging that includes bispecific antibodies, antibody-drug conjugates and other novel feats of protein engineering. Together, these new biologic drugs seek to maximize tumor killing while minimizing immune and healthy tissue toxicities. The panel will discuss this new wave of innovation and what it means for the treatment of solid tumors.

Moderator
Daniel Haber, MD, PhD
Director, Mass General Cancer Center; Kurt J. Isselbacher Professor of Oncology, HMS

Bill Lundberg, MD
CEO, Merus
Thomas Schuetz, MD, PhD
CEO & Co-Founder, Compass Therapeutics
Fred Schwarzer
CEO, IGM Biosciences